Wikipedia:Articles for deletion/Gancotamab

The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was delete. Sandstein 19:32, 1 October 2018 (UTC)[reply]

Gancotamab[edit]

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

too early for an article. except a name (tho the structural formula is in the reference) No information provided about state of any therapeutic trials. No information about why it might be "designed for the treatment of cancer" I question whether it is appropriate to have an article until there is some actual published information. DGG ( talk ) 06:35, 24 September 2018 (UTC)[reply]

Delete in presumed absence of inofficial practices to keep these phantoms. Name registered + in development seems a mite too early to have an article. --Elmidae (talk · contribs) 16:03, 25 September 2018 (UTC)[reply]
Merge with Merrimack Pharmaceuticals, since it is related to that. Leo1pard (talk) 16:59, 25 September 2018 (UTC)[reply]
Delete or Redirect to Merrimack. With development halted, it's not likely that there will be any more information to write an article with anytime soon. Natureium (talk) 17:56, 25 September 2018 (UTC)[reply]

&Commment Not appropriate for a merge unti l it becomes an accepted drug. DGG ( talk ) 08:55, 29 September 2018 (UTC)[reply]

Delete - could be interpreted as promotional as well as non-notable. Deb (talk) 14:35, 1 October 2018 (UTC)[reply]

The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.